Robert M Wenham, Chair of Department of Gynecologic Oncology at Moffitt Cancer Center, shared a post on LinkedIn:
“PROGRESS IN OVARIAN CANCER. Our work laid the foundation for Keynote-B96, improving PFS and among the longest overall survivals reported in platinum-resistant ovarian cancer. I am deeply grateful to my outstanding collaborators who tested my hypothesis that metronomic taxane therapy could confer immunomodulatory effects and sensitize ovarian tumors to immune checkpoint inhibition. A meaningful step forward bringing IO to this cancer and treatment for patients.”
Title: A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer
Authors: Robert M. Wenham, Andrea L. Buras, Sarah W. Gordon, Junmin Whiting, Brooke L. Fridley, Denise Dorman, Sachin M. Apte, Hye Sook Chon, Mian M. Shahzad, Leslie M. Randall, Laura J. Havrilesky, Brittany A. Davidson, Angeles Alvarez Secord
